talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
Published 1 month ago • 84 plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
6:07
magnetismm-3: elranatamab in r/r multiple myeloma naive to bcma-directed therapy
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
1:45
evaluating nivolumab-based therapy to restore t-cell fitness in patients with r/r multiple myeloma
-
1:29
managing toxicities associated with immunotherapy in multiple myeloma
-
2:49
trimm-2 update: talquetamab daratumumab in r/r multiple myeloma
-
4:44
investigating immune dynamics in multiple myeloma treated with talquetamab monotherapy
-
8:57
outcomes of sct in t-all and t-lbl
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
7:12
key multiple myeloma abstracts presented at 2024 asco and eha meeting
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
1:59
the role of proteasome inhibitors in the treatment of r/r multiple myeloma
-
2:34
the effect of dose reduction of talquetamab in patients with r/r mm: results from monumental-1
-
2:35
resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
-
4:15
talquetamab: gprc5d-cd3 bispecific antibody in r/r myeloma
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
0:49
management of patients with penta-class refractory myeloma
-
0:59
the treatment of patients with t(11;14) myeloma
-
3:04
monumental-1 update: talquetamab in r/r multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma